Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 12:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 63 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Opioid Induced Constipation Clear all

Conditions: Opioid-Induced Constipation
Interventions: Linaclotide 145 micrograms, Linaclotide 290 micrograms, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 77
States / cities: Anniston, Alabama • Foley, Alabama • Phoenix, Arizona + 67 more

Conditions: Bowel Dysfunction, Constipation
Interventions: Placebo, Alvimopan, Alviompan; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 485 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 119
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 104 more

Conditions: Constipation
Interventions: N-methylnaltrexone bromide (MOA-728), placebo; Drug · Other
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 78
States / cities: Mobile, Alabama • Sun City, Arizona • Tucson, Arizona + 69 more

Conditions: Opioid-Induced Constipation
Interventions: NKTR-118, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 81
States / cities: Huntsville, Alabama • Casa Grande, Arizona • Phoenix, Arizona + 78 more

Conditions: OIC
Interventions: ALKS 37, Placebo; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 13
States / cities: Anaheim, California • Orange, California • Daytona Beach, Florida + 10 more

Conditions: Opioid-induced Constipation
Interventions: Tegaserod; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Timeline: 2007
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Opioid-Induced Bowel Dysfunction
Interventions: Lubiprostone 24; Drug
Lead sponsor: Sucampo Pharma Americas, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 439 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 120
States / cities: Birmingham, Alabama • Hueytown, Alabama • Mobile, Alabama + 95 more

Conditions: Opioid-induced Constipation
Interventions: Tegaserod; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 360 participants
Timeline: 2006 – 2007
U.S. locations: 57
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 49 more

Conditions: Constipation Drug Induced
Interventions: Methylnaltrexone Bromide 150 mg Oral Tablet, Methylnaltrexone Bromide 12 MG/0.6 ML Subcutaneous Solution [RELISTOR]_#1, Naloxegol 25 MG Oral Tablet; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Opioid-induced Constipation
Interventions: Naldemedine, Lubiprostone, Naloxegol; Drug
Lead sponsor: BioDelivery Sciences International; Industry
Eligibility: 18 Years and older
Enrollment: 34,532 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: Opioid-Induced Constipation (OIC)
Interventions: NKTR-118, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 84 Years
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 90
States / cities: Birmingham, Alabama • Calera, Alabama • Glendale, Arizona + 87 more

Conditions: Opioid-induced Constipation
Interventions: Placebo, Naldemedine; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years and older
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 49
States / cities: Phoenix, Arizona • Sun Lakes, Arizona • Little Rock, Arkansas + 46 more

Conditions: Opioid Induced Constipation
Interventions: Polyethylene Glycol 3350, Movantik; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 84 Years
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 53
States / cities: Huntsville, Alabama • Phoenix, Arizona • Anaheim, California + 46 more

Conditions: Constipation, Bowel Dysfunction
Interventions: alvimopan, placebo; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 69
States / cities: Tucson, Arizona • Hot Springs, Arkansas • Duarte, California + 58 more

Conditions: Advanced Illness Patients With Opioid Induced Constipation
Interventions: SC Methylnaltrexone, SC Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Tarrytown, New York

Conditions: Opioid Induced Constipation
Interventions: TD-1211, Placebo; Drug
Lead sponsor: Glycyx Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Foley, Alabama

Conditions: Opioid-induced Constipation
Interventions: Naldemedine, Placebo; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 553 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 49
States / cities: Birmingham, Alabama • Homewood, Alabama • Goodyear, Arizona + 46 more

Conditions: Constipation
Interventions: MOA-728; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 67
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 53 more

Conditions: Cancer, Constipation, Pain
Interventions: Naloxegol, Placebo; Drug
Lead sponsor: Hospice of Henderson County, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: New York, New York • Flat Rock, North Carolina • Cleveland, Ohio

Conditions: Opioid Induced Constipation
Interventions: naloxegol, non-PAMORA; Drug
Lead sponsor: Valinor Pharma LLC; Industry
Eligibility: Not listed
Enrollment: 8,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 2
States / cities: Wilmington, Delaware • Hines, Illinois

Conditions: Opioid-Induced Constipation
Interventions: methylnaltrexone, placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 4
States / cities: Laguna Hills, California • Lancaster, California • Flat Rock, North Carolina + 1 more

Conditions: Opioid-Induced Constipation (OIC)
Interventions: NKTR-118, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 84 Years
Enrollment: 652 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 91
States / cities: Birmingham, Alabama • Calera, Alabama • Glendale, Arizona + 88 more

Conditions: Constipation
Interventions: TD-1211 Dose 1, TD-1211 Dose 2; Drug
Lead sponsor: Glycyx Therapeutics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Bowel Dysfunction, Constipation
Interventions: alvimopan, Placebo; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 137
States / cities: Birmingham, Alabama • Calera, Alabama • Muscle Shoals, Alabama + 114 more

Search by objective public record fields.

Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain

Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain

Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain

Assessment of Efficacy and Safety in Relieving Opioid-induced Constipation in Patients With Cancer-related Pain

ALK37-007: Evaluation of Safety and Efficacy of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)

Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.

Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone

Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.

Methylnaltrexone vs Naloxegol in the Treatment of Opioid-Induced Constipation

Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation

A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation

A Study of Naldemedine (S-297995) for the Treatment of Opioid-Induced Constipation in Adults With Non-Malignant Chronic Pain Receiving Opioid Therapy

To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation

Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication

A a Single Dose Efficacy Study in Inducing Laxation in Advance Illness Patients

A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced Constipation

Efficacy and Safety of Naldemedine in Treating Opioid-induced Constipation

Study Evaluating Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction (OIBD) in Subjects With Chronic Non-Malignant Pain

Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)

Naloxegol US PMR CV Safety.

Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects

Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation

TD-1211 Single-Dose Study in Elderly and Young Healthy Subjects

Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain